Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2021

Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

1 UMMC - University of Mississippi Medical Center
2 Charité Campus Virchow-Klinikum (CVK)
3 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
4 DZHK - German Center for Cardiovascular Research
5 BCRT - Berlin-Brandenburg Center for Regenerative Medicine [Berlin, Germany]
6 Department of Internal Medicine, Dow University of Health Sciences
7 University of Warwick [Coventry]
8 Vifor Pharma Ltd [Glattbrugg, Switzerland]
9 NKUA - National and Kapodistrian University of Athens
10 UOA - Université d'Athènes
11 “Attikon” University Hospital
12 UMG - University Medical Center Göttingen
13 UMKC - University of Missouri [Kansas City]
14 Saint Luke's Mid America Heart Institute
15 Karolinska Institutet [Stockholm]
16 UniBs - Università degli Studi di Brescia = University of Brescia
17 Civic Hospital of Brescia
18 CMU - Central Michigan University
19 NOVA - Universidade Nova de Lisboa = NOVA University Lisbon
20 Faculdade de Medicina [Lisboa]
21 Hospital de Santa Maria [Lisboa]
22 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
23 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
24 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
25 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
26 UMCG - University Medical Center Groningen [Groningen]
27 University of Groningen [Groningen]
28 University of Maryland School of Medicine
29 University of Michigan [Ann Arbor]
Javed Butler
Ileana L Piña
Bertram Pitt

Résumé

Aims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enrol ~820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to ≥50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi Use Score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive HF medication. Conclusion: The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use.
Fichier principal
Vignette du fichier
ejhf.2386.pdf (1.59 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03467277 , version 1 (06-12-2021)

Identifiants

Citer

Javed Butler, Stefan D Anker, Tariq Jamal Siddiqi, Andrew J S Coats, Fabio Dorigotti, et al.. Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. European Journal of Heart Failure, 2021, ⟨10.1002/ejhf.2386⟩. ⟨hal-03467277⟩
103 Consultations
57 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More